Page last updated: 2024-12-07

(20s)-20-hydroxycholesterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## (20S)-20-hydroxycholesterol: A Key Regulator of Cholesterol Homeostasis and Beyond

**(20S)-20-hydroxycholesterol** is a naturally occurring sterol, a type of lipid molecule, that plays a crucial role in the regulation of cholesterol metabolism and other cellular processes. It is produced in the liver and other tissues through the enzymatic oxidation of cholesterol by the enzyme **cholesterol 20-hydroxylase (CYP46A1)**.

**Importance for Research:**

(20S)-20-hydroxycholesterol has garnered significant interest in research due to its multifaceted roles in various biological systems. Here's a breakdown:

**1. Cholesterol Homeostasis:**

* **Neurosteroid:** (20S)-20-hydroxycholesterol acts as a neurosteroid in the central nervous system. It is thought to modulate neuronal function and play a role in brain development.
* **Brain Cholesterol Metabolism:** This sterol facilitates the efflux of cholesterol from the brain, preventing cholesterol accumulation and neurotoxicity.
* **Feedback Regulation of Cholesterol Synthesis:** It suppresses the synthesis of cholesterol in the liver by inhibiting the enzyme HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis.

**2. Immune System Modulation:**

* **Anti-inflammatory Effects:** (20S)-20-hydroxycholesterol exhibits anti-inflammatory properties by suppressing the production of pro-inflammatory cytokines like TNF-alpha.
* **Inhibition of Viral Entry:** Studies suggest that it can inhibit the entry of certain viruses into cells, including HIV and influenza virus.

**3. Cancer Research:**

* **Anti-cancer Activity:** Some research suggests that (20S)-20-hydroxycholesterol may have anti-cancer properties, potentially inhibiting the growth and proliferation of certain cancer cells.
* **Targeting CYP46A1:** Research is exploring the potential of targeting the enzyme CYP46A1 to modulate (20S)-20-hydroxycholesterol levels for therapeutic purposes in cancer treatment.

**4. Neurological Disorders:**

* **Alzheimer's Disease:** (20S)-20-hydroxycholesterol has been linked to Alzheimer's disease due to its role in cholesterol metabolism and its potential to modulate amyloid-beta production.
* **Multiple Sclerosis:** Research suggests that it might have therapeutic potential in multiple sclerosis due to its neuroprotective and anti-inflammatory effects.

**5. Drug Development:**

* **Novel Therapeutic Targets:** The diverse roles of (20S)-20-hydroxycholesterol make it a potential target for developing new drugs for various diseases, including neurological disorders, cancer, and infectious diseases.

**Overall, (20S)-20-hydroxycholesterol is a fascinating molecule with a complex interplay of functions. Research continues to uncover its diverse biological roles and its potential therapeutic applications.**

20-hydroxycholesterol: RN given refers to (20S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

20-hydroxycholesterol : An oxysterol that is cholesterol substituted by a hydroxy group at position 20. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID121935
CHEMBL ID173898
CHEBI ID1296
SCHEMBL ID288274
MeSH IDM0085621

Synonyms (46)

Synonym
(3beta)-cholest-5-ene-3,20-diol
cholest-5-ene-3beta,20-diol
20(s)-hydroxycholesterol
CHEBI:1296 ,
(20s)-20-hydroxycholesterol
bdbm20175
(1s,2r,5s,10s,11s,14s,15s)-14-[(2s)-2-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-7-en-5-ol
20alpha-hydroxycholesterol
20-hydroxycholesterol
C05500
516-72-3
CHEMBL173898
cholest-5-en-3beta,20-diol
LMST01010201
(3s,8s,9s,10r,13s,14s,17s)-17-[(2s)-2-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
(3alpha,8alpha)-cholest-5-ene-3,20-diol
HCD ,
nat-20(s)-hydroxycholesterol
cholest-5-ene-3,20-diol, (3beta)-
(20s)-cholest-5-ene-3beta,20-diol
20s-cholest-5-ene-3beta,20-diol
30060wal99 ,
cholest-5-ene-3beta,20-diol, (20s)-
cholest-5-ene-3beta,20alpha-diol
unii-30060wal99
20alpha-hydroxy cholesterol
SCHEMBL288274
cholest-5-ene-3.beta.,20-diol, (20s)-
20.alpha.-hydroxycholesterol
20s-cholest-5-ene-3.beta.,20-diol
cholest-5-ene-3,20-diol, (3.beta.)-
cholest-5-ene-3.beta.,20.alpha.-diol
cholest-5-en-3beta,20alpha-diol
mfcd16661190
20alpha-hydroxycholesterol, analytical standard
Q27067423
HY-12316
20a-hydroxycholesterol
CS-0011056
5-cholestene-3beta,20alpha-diol
20 alpha -hydroxy cholesterol
20?-hydroxy cholesterol
3beta-cholest-5-ene-3,20-diol
DTXSID70862096
PD053694
AKOS040732269

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We now demonstrate that this osteogenic combination of oxysterols prevents the adverse effects of oxidative stress on differentiation of M2 cells into mature osteoblastic cells."( Osteogenic oxysterols inhibit the adverse effects of oxidative stress on osteogenic differentiation of marrow stromal cells.
Amantea, CM; Hahn, TJ; Kha, HT; Parhami, F; Richardson, JA; Shouhed, D, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Dose-response depression in both hCG- and db-cAMP-stimulated T production were seen with Cd2+, Co2+, Cu2+, Hg2+, Ni2+, and Zn2+ treatment."( Effect of cadmium and other metal cations on in vitro Leydig cell testosterone production.
Laskey, JW; Phelps, PV, 1991
)
0.28
" The hCG dose-response curve was shifted to the right by the addition of IL-2."( Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis.
Calkins, JH; Guo, H; Lin, T; Sigel, MM, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
20-hydroxy steroidAny hydroxy steroid that in which the steroid skeleton contains a hydroxy substituent at position 20.
oxysterolAn oxygenated derivative of cholesterol
3beta-hydroxy-Delta(5)-steroidAny 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor ROR-gammaHomo sapiens (human)EC50 (µMol)0.02700.02000.70359.0000AID1709549
Oxysterols receptor LXR-alphaHomo sapiens (human)EC50 (µMol)0.47000.00010.63026.7100AID101835; AID1797959
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (47)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIOxysterols receptor LXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of triglyceride biosynthetic processOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of cholesterol effluxOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of cholesterol storageOxysterols receptor LXR-alphaHomo sapiens (human)
intracellular receptor signaling pathwayOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of lipid transportOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of cholesterol transportOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of transporter activityOxysterols receptor LXR-alphaHomo sapiens (human)
response to progesteroneOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathwayOxysterols receptor LXR-alphaHomo sapiens (human)
phosphatidylcholine acyl-chain remodelingOxysterols receptor LXR-alphaHomo sapiens (human)
cholesterol homeostasisOxysterols receptor LXR-alphaHomo sapiens (human)
regulation of circadian rhythmOxysterols receptor LXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of macrophage activationOxysterols receptor LXR-alphaHomo sapiens (human)
apoptotic cell clearanceOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of fatty acid biosynthetic processOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of proteolysisOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of pinocytosisOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of inflammatory responseOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of lipoprotein lipase activityOxysterols receptor LXR-alphaHomo sapiens (human)
positive regulation of protein metabolic processOxysterols receptor LXR-alphaHomo sapiens (human)
lipid homeostasisOxysterols receptor LXR-alphaHomo sapiens (human)
sterol homeostasisOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayOxysterols receptor LXR-alphaHomo sapiens (human)
triglyceride homeostasisOxysterols receptor LXR-alphaHomo sapiens (human)
cellular response to lipopolysaccharideOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of pancreatic juice secretionOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of secretion of lysosomal enzymesOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of cold-induced thermogenesisOxysterols receptor LXR-alphaHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressOxysterols receptor LXR-alphaHomo sapiens (human)
cell differentiationOxysterols receptor LXR-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
transcription cis-regulatory region bindingOxysterols receptor LXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingOxysterols receptor LXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificOxysterols receptor LXR-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificOxysterols receptor LXR-alphaHomo sapiens (human)
DNA bindingOxysterols receptor LXR-alphaHomo sapiens (human)
nuclear receptor activityOxysterols receptor LXR-alphaHomo sapiens (human)
protein bindingOxysterols receptor LXR-alphaHomo sapiens (human)
zinc ion bindingOxysterols receptor LXR-alphaHomo sapiens (human)
cholesterol bindingOxysterols receptor LXR-alphaHomo sapiens (human)
chromatin DNA bindingOxysterols receptor LXR-alphaHomo sapiens (human)
sterol response element bindingOxysterols receptor LXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingOxysterols receptor LXR-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleusOxysterols receptor LXR-alphaHomo sapiens (human)
nucleoplasmOxysterols receptor LXR-alphaHomo sapiens (human)
cytoplasmOxysterols receptor LXR-alphaHomo sapiens (human)
cytosolOxysterols receptor LXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexOxysterols receptor LXR-alphaHomo sapiens (human)
chromatinOxysterols receptor LXR-alphaHomo sapiens (human)
receptor complexOxysterols receptor LXR-alphaHomo sapiens (human)
nucleusOxysterols receptor LXR-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID768317Binding affinity to human GFP-tagged NPC1L1 L1072T/L1168I mutant expressed in HEK293 cells assessed as localization to endoplasmic reticulum and plasma membrane at 10 uM after 24 hrs by fluorescence microscopic analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect.
AID1771778Antagonist activity at SMO in mouse NIH3T3 cells preincubated for 2 hrs followed by ShhN stimulation and measured after 24 hrs in presence of GDC0449 by Bright-Glo luciferase assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.
AID1771773Agonist activity at SMO in mouse NIH3T3 cells assessed as fluorescent intensity of ciliary SMO incubated for 12 hrs by fluorescence method2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.
AID1709562Binding affinity to 2-chloro-5-nitro-N-o-tolylbenzamide-ligated recombinant human N-terminal His6-tagged RORgammat (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 10 uM in presence of 2-chloro-5-2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID1709557Orthosteric agonist activity at 2-chloro-N-(2,6-dimethylphenyl)-5-nitrobenzamide-ligated recombinant human N-terminal His6-tagged RORgammat ligand binding domain (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as increase in coacti2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID101835Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha.
AID509545Agonist activity at hedgehog receptor2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Modulators of the hedgehog signaling pathway.
AID1709555Orthosteric agonist activity at 2-chloro-5-nitro-N-o-tolylbenzamide-ligated recombinant human N-terminal His6-tagged RORgammat ligand binding domain (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as increase in coactivator, N-term2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID1179741Binding affinity to FLAG/tGFP-tagged NPC1 I1061T mutant (unknown origin) expressed in HEK293 cells assessed as localization at 10 uM after 24 hrs by fluorescence microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Structure-activity relationships of oxysterol-derived pharmacological chaperones for Niemann-Pick type C1 protein.
AID101844Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha.
AID1709564Binding affinity to 2-chloro-5-nitro-N-(2-(trifluoromethyl)phenyl)benzamide-ligated recombinant human N-terminal His6-tagged RORgammat (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 10 uM in pre2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID1709563Binding affinity to 2-chloro-N-(2,6-dimethylphenyl)-5-nitrobenzamide-ligated recombinant human N-terminal His6-tagged RORgammat (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 10 uM in presence o2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID1771772Agonist activity at SMO in mouse NIH3T3 cells assessed as induction of SMO accumulation in primary cilia incubated for 12 hrs by fluorescence method2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.
AID695018Agonist activity at LXR in mouse C3H10T1/2 cells assessed as fold increase in ABCA1 expression at 5 uM by RT-PCR analysis relative to control2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Structure-activity relationships for side chain oxysterol agonists of the hedgehog signaling pathway.
AID1771776Antagonist activity at SMO in mouse NIH3T3 cells preincubated for 2 hrs followed by SAG stimulation and measured after 24 hrs in presence of GDC0449 by Bright-Glo luciferase assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.
AID1709551Orthosteric agonist activity at GW9662-ligated recombinant human N-terminal His6-tagged RORgammat ligand binding domain (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as increase in coactivator, N-terminal biotinylated SRC-1 box2 2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID1709549Orthosteric agonist activity at recombinant human N-terminal His6-tagged RORgammat ligand binding domain (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as increase in coactivator, N-terminal biotinylated SRC-1 box2 peptide recruit2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID1771771Agonist activity at SMO in mouse NIH3T3 cells assessed as induction of SMO accumulation in primary cilia incubated for 12 hrs by AlexaFluor 488/ DAPI staining based immunofluorescence method2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.
AID1771777Agonist activity at SMO in mouse NIH3T3 cells preincubated for 2 hrs followed by SAG stimulation and measured after 24 hrs in presence of GDC0449 by Bright-Glo luciferase assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.
AID695019Selectivity ratio of agonist activity at Hh receptor over agonist activity at LXR in mouse C3H10T1/2 cells2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Structure-activity relationships for side chain oxysterol agonists of the hedgehog signaling pathway.
AID1709561Binding affinity to recombinant human N-terminal His6-tagged RORgammat (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 10 uM by thermal shift assay2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID1709559Orthosteric agonist activity at 2-chloro-5-nitro-N-(2-(trifluoromethyl)phenyl)benzamide-ligated recombinant human N-terminal His6-tagged RORgammat ligand binding domain (265 to 518 residues) expressed in Escherichia coli BL21 (DE3) assessed as increase in2021ACS medicinal chemistry letters, Apr-08, Volume: 12, Issue:4
Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site.
AID695017Agonist activity at Hh receptor in mouse C3H10T1/2 cells assessed as fold increase in Gli1 expression at 5 uM by RT-PCR analysis relative to control2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Structure-activity relationships for side chain oxysterol agonists of the hedgehog signaling pathway.
AID1797959Cell-Free Ligand Sensing Assay (LiSA)-LXRalpha-SRC1 Assay from Article 10.1021/jm0004749: \\Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha.\\2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (31.37)18.7374
1990's11 (21.57)18.2507
2000's7 (13.73)29.6817
2010's10 (19.61)24.3611
2020's7 (13.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.70 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (96.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]